• Startseite
  • Aktien
  • Minerva Neurosciences Aktie

    • Minerva Neurosciences Aktie

    7,20 $ +0,70% +0,05 $
    In Euro: 5,8675 € | 20.04.18 Nasdaq | Mehr Kurse »
    WKN: A1171S
    ISIN: US6033801068
    US-Symbol: NERV
    Typ: Aktie
    Kaufen
    + Depot
    Minerva Neurosciences Aktie Chart

    Performance Minerva Neurosciences Aktie

    1 Woche 1 Monat 3 Monate Lfd. Jahr 1 Jahr 3 Jahre
    Kurs 6,90 $ 6,40 $ 6,60 $ 6,05 $ 6,80 $ 5,59 $
    Änderung +4,35% +12,50% +9,09% +19,01% +5,88% +28,80%

    Nachrichten zur Minerva Neurosciences Aktie

    09.04.18 Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder GlobeNewswire
    15.03.18 Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22 GlobeNewswire
    12.03.18 Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates GlobeNewswire
    05.03.18 Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018 GlobeNewswire
    05.02.18 Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director GlobeNewswire
    21.12.17 Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With... GlobeNewswire

    Analysen

    Kaufen Halten Verkaufen
    Analysten 0 0 0
    Markt-Lotsen 0 0 0

    Aktie & Unternehmen

    Branche Biotechnologie
    Herkunft USA
    Website ir.minervaneurosciences.com
    Aktienanzahl 27,9 Mio. (Stand: 31.05.16)
    Marktkap. 201,2 Mio. $

    Dividenden & Splits

    Keine Daten im genannten Zeitraum vorhanden

    Ähnliche Aktien

    Name
    last
    change_rel
     
    Trevena 1,43 € +1,42%
    Celgene 73,08 € +0,26%
    Akers Biosciences 0,439 € +2,81%
    Eleven Biotherapeutics 1,39 € +18,80%
    Cannabics Pharmaceuticals 0,853 € +4,41%